Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PHVS Stock Forecast 2025-2026
$16.61
Current Price
$873.52M
Market Cap
Buy 8
Hold 0
Sell 1
Wall St Analyst Ratings
Distance to PHVS Price Targets
+230.6%
To High Target of $54.91
+91.8%
To Median Target of $31.86
-15.9%
To Low Target of $13.96
PHVS Price Momentum
-2.2%
1 Week Change
+18.6%
1 Month Change
-18.4%
1 Year Change
-13.4%
Year-to-Date Change
-34.9%
From 52W High of $25.50
+44.3%
From 52W Low of $11.51
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Pharvaris (PHVS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PHVS and similar high-potential opportunities.
Latest PHVS Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, PHVS has a bullish consensus with a median price target of $31.86 (ranging from $13.96 to $54.91). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $16.61, the median forecast implies a 91.8% upside. This outlook is supported by 8 Buy, 0 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PHVS Analyst Ratings
8
Buy
0
Hold
1
Sell
PHVS Price Target Range
Low
$13.96
Average
$31.86
High
$54.91
Current: $16.61
Latest PHVS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PHVS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 14, 2025 | Cantor Fitzgerald | Timur Ivannikov | Overweight | Maintains | $25.00 |
| Apr 29, 2025 | Cantor Fitzgerald | Steven Seedhouse | Overweight | Initiates | $28.00 |
| Mar 3, 2025 | Citizens Capital Markets | Jonathan Wolleben | Market Outperform | Reiterates | $55.00 |
| Jan 31, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $55.00 |
| Sep 19, 2024 | Jones Trading | Debanjana Chatterjee | Buy | Initiates | $46.00 |
| Sep 6, 2024 | Oppenheimer | Justin Kim | Outperform | Maintains | $42.00 |
| Jul 3, 2024 | Oppenheimer | Justin Kim | Outperform | Maintains | $38.00 |
| May 9, 2024 | Wedbush | Laura Chico | Outperform | Maintains | $31.00 |
| Apr 22, 2024 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $34.00 |
| Apr 15, 2024 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $34.00 |
| Apr 11, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $50.00 |
| Apr 11, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $35.00 |
| Mar 19, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $35.00 |
| Feb 14, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $49.00 |
| Jan 23, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $49.00 |
| Dec 7, 2023 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $35.00 |
| Dec 7, 2023 | B of A Securities | Tazeen Ahmad | Underperform | Maintains | $11.00 |
| Nov 14, 2023 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $32.00 |
| Nov 3, 2023 | Wedbush | Laura Chico | Outperform | Maintains | $24.00 |
| Sep 25, 2023 | Wedbush | Laura Chico | Outperform | Initiates | $27.00 |
Pharvaris N.V. (PHVS) Competitors
The following stocks are similar to Pharvaris based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Pharvaris N.V. (PHVS) Financial Data
Pharvaris N.V. has a market capitalization of $873.52M with a P/E ratio of -6.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -52.2%.
Valuation Metrics
Market Cap
$873.52M
Enterprise Value
$707.63M
P/E Ratio
-6.7x
PEG Ratio
-5.3x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+26.1%
Current Ratio
11.1x
Debt/Equity
0.3x
ROE
-52.2%
ROA
-31.9%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Pharvaris N.V. (PHVS) Business Model
About Pharvaris N.V.
What They Do
Develops therapies for hereditary angioedema.
Business Model
Pharvaris N.V. generates revenue by discovering, developing, and commercializing innovative biopharmaceutical therapies, specifically targeting hereditary angioedema (HAE) and other related conditions. The company focuses on creating oral treatment alternatives to traditional injectable therapies, which enhances patient accessibility and convenience.
Additional Information
Headquartered in Leiden, the Netherlands, Pharvaris is dedicated to addressing unmet medical needs within the biopharmaceutical industry. Its research and development initiatives emphasize advancing treatment options for rare genetic diseases, positioning the company as a significant player in biotechnology and reflecting the growing demand for targeted therapies in healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
108
CEO
Mr. Berndt Axel Edvard Modig CPA, M.B.A.
Country
Switzerland
IPO Year
2021
Website
pharvaris.comPharvaris N.V. (PHVS) Latest News & Analysis
Latest News
Quick Summary
Pharvaris (Nasdaq: PHVS) reported Q1 2025 financial results, focusing on its oral bradykinin B2 receptor antagonists for treating hereditary and acquired angioedema.
Why It Matters
Pharvaris's Q1 2025 financial results and updates on their drug development for bradykinin-mediated diseases signal potential growth opportunities and risks for investors in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Deucrictibant's potential treatment applications are expanding for individuals with bradykinin-mediated angioedema, indicating growth opportunities in therapeutic markets.
Why It Matters
The expansion of treatment applications for deucrictibant could enhance market potential and revenue for the company, influencing stock performance and investor sentiment in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
1 month ago
Quick Summary
Pharvaris (Nasdaq: PHVS) reported its Q4 and full-year 2024 financial results on April 7, 2025. The company is focused on developing oral bradykinin B2 receptor antagonists for angioedema treatments.
Why It Matters
Pharvaris' financial results and updates on drug development for bradykinin-mediated diseases may impact stock performance, indicating potential growth or risk based on clinical progress and market demand.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
1 month ago
Quick Summary
Pharvaris (Nasdaq: PHVS) received orphan designation from the European Commission for its drug deucrictibant, aimed at treating bradykinin-mediated angioedema.
Why It Matters
The European Commission's orphan designation for deucrictibant boosts Pharvaris's market potential, signaling strong interest in its drug pipeline and potentially increasing stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pharvaris (Nasdaq: PHVS) presented safety and efficacy data for deucrictibant at a recent conference. It is in pivotal Phase 3 studies for treating bradykinin-mediated diseases.
Why It Matters
Pharvaris's positive data on deucrictibant in pivotal Phase 3 studies could lead to market approval, potentially boosting revenue and stock value, impacting investor sentiment significantly.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pharvaris (Nasdaq: PHVS) will present at the Leerink Partners Global Healthcare Conference from March 10-12, 2025, discussing their oral bradykinin B2 receptor antagonists for treating angioedema.
Why It Matters
Pharvaris's participation in a major healthcare conference signals potential visibility and investor interest, which could influence stock performance and market perception of its therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PHVS Stock
What is Pharvaris N.V.'s (PHVS) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Pharvaris N.V. (PHVS) has a median price target of $31.86. The highest price target is $54.91 and the lowest is $13.96.
Is PHVS stock a good investment in 2025?
According to current analyst ratings, PHVS has 8 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $16.61. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PHVS stock?
Wall Street analysts predict PHVS stock could reach $31.86 in the next 12 months. This represents a 91.8% increase from the current price of $16.61. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pharvaris N.V.'s business model?
Pharvaris N.V. generates revenue by discovering, developing, and commercializing innovative biopharmaceutical therapies, specifically targeting hereditary angioedema (HAE) and other related conditions. The company focuses on creating oral treatment alternatives to traditional injectable therapies, which enhances patient accessibility and convenience.
What is the highest forecasted price for PHVS Pharvaris N.V.?
The highest price target for PHVS is $54.91 from at , which represents a 230.6% increase from the current price of $16.61.
What is the lowest forecasted price for PHVS Pharvaris N.V.?
The lowest price target for PHVS is $13.96 from at , which represents a -15.9% decrease from the current price of $16.61.
What is the overall PHVS consensus from analysts for Pharvaris N.V.?
The overall analyst consensus for PHVS is bullish. Out of 11 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $31.86.
How accurate are PHVS stock price projections?
Stock price projections, including those for Pharvaris N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 18, 2025 1:08 AM UTC